
Recent advances have transformed the management of compensated advanced chronic liver disease (cACLD), aiming to prevent progression to decompensated ACLD (dACLD), which carries high mortality. Clinically significant portal hypertension (CSPH) drives this transition, with a threshold of ≥10 mmHg. Innovations include noninvasive tests (NITs) to identify CSPH, aetiological therapies to halt or reverse cirrhosis, and non-selective β-blockers to prevent complications like ascites.
Like
Save
Share